Researchers have puzzled over how
Sarcocystis neurona, the single-celled
protozoan parasite notorious for causing
equine protozoal myeloencephalitis (EPM),
travels from the intestine, through the
blood-brain barrier, and into the central
nervous system to cause the neurological
signs that we see in horses with EPM. A team
at the Virginia Maryland Regional College of
Veterinary Medicine (VMRCVM) has been
studying the mechanisms by which S.
neurona causes disease, trying to find
ways to protect horses from EPM, and
developing additional tests for diagnosing
EPM.
The S. neurona life cycle involves
the definitive host (an opossum) that feeds
on the muscles of dead intermediate hosts
(such as the striped skunk, raccoon,
nine-banded armadillo, and cat). The
protozoan parasite advances to a specific
stage of its life cycle (sarcocyst) in the
intermediate host's muscle before an
omnivore such as the opossum eats the
muscle, which continues the parasite's life
cycle. The horse contracts EPM by
inadvertently consuming infected opossum
droppings while grazing or while eating
contaminated feed or hay.
It's a complicated journey from the
digestive tract to the central nervous
system that scientists have long tried to
understand. "Others have demonstrated that
S. neurona can infect leukocytes
(white blood cells) and endothelial cells
(those in the lining of blood vessels),"
said Sharon Witonsky, DVM, PhD, Dipl. ACVIM,
associate professor in the large animal
clinical sciences at Virginia Tech in
Blacksburg, Va. "It appears plausible that
S. neurona could infect leukocytes
in the body. These infected leukocytes could
then cross the blood-brain barrier, where
S. neurona may be released through
some unknown mechanism. Once there, S.
neurona could cause encephalitis
(inflammation of the brain and spinal cord,
as seen in EPM)."
The Horse reported in October about
Witonsky's team's discovery of S.
neurona in specific types of white
blood cells, and this could explain the
parasite's ability to cross the blood-brain
barrier. Witonsky explained that Siobhan
Ellison, DVM, PhD, of Pathogenes Inc., had
already been using a leukocyte infection
model several years prior to the current
study and has published work on the model.
"So in our study we wanted to more
specifically demonstrate that the cells
could be infected and begin to determine the
cell types," she said. "We wanted to
determine in a more defined (in vitro,
outside the living body in the laboratory)
system, whether S. neurona could
infect equine peripheral blood leukocytes,
and if possible, what cells S. neurona
preferentially infects.We (confirmed
Ellison's findings) that S. neurona
can infect leukocytes, and based on the
study, it appears that S. neurona
preferentially infects monocytes." Monocytes
are a particular type of white blood cell
found in the circulation that convert into
active macrophages (specialized white blood
cells that fight infection) when they enter
the tissue.
She continued, "Subsequent experiments will
determine what subsets (i.e. specific
T-lymphocyte subsets (CD4, CD8),
B-lymphocytes, and monocytes and/or
neutrophils) that S. neurona
preferentially infects."
The team is using both equine and rodent
models to determine how the horse's body can
be protected from S. neurona
infection and the best ways to determine
infection. "We have determined that a
cell-mediated immune response, composed of
CD8 cells (specialized white blood cells
with CD8 receptors that recognize antigens
on the surface of infected cells and bind to
the infected cells and kill them) is
critical to protection in mice," she said.
"We expect there to be similar findings in
horses, but this work has not yet been
conducted."
They have also determined that "both
experimentally and naturally infected horses
develop suppressed in vitro proliferation
responses to a particular mitogen (a
substance that causes cell division)," she
said, meaning that the agent suppressed the
proliferation of some of the horses' cells
under very specific conditions. It is not
clear how this correlates to the horse's
overall immune response as these are results
have been done with cells that have been
removed from the horse. One manuscript has
been published on this finding, and another
is under review. "We are determining the
mechanisms of this suppression. Individuals
of the group have also been involved in the
evaluation of therapeutic agents either in
vitro or in vivo (in the live
animal)."
Witonsky stresses that the team collaborates
with researchers beyond the institutions
that make up the VMRCVM. "We have an
excellent team of researchers at Virginia
Tech, combined with colleagues at other
institutions," she said. "The Virginia
Maryland Regional College of Veterinary
Medicine group consists of myself
(immunology, large animal internal
medicine), David Lindsay (PhD, parasitology),
Robert Gogal Jr. (DVM, immunology), Robert
Duncan Jr. (BS, DVM, PhD, Dipl. ACVP,
pathology), Yasuhiro Suzuki (PhD, DMSc,
immunology) and Virginia Buechner-Maxwell
(DVM, MS, Dipl. ACVIM, large animal internal
medicine). Additionally, we have strong
collaborations with Ellison and Frank
Andrews (internal medicine, University of
Tennessee). We have just initiated a
collaboration with Dr. Dan Howe (PhD) at
Gluck (the University of Kentucky's Gluck
Equine Research Center).